Summary
Botulinum neurotoxin (BoNT) treatment has been used extensively for the treatment of cervical dystonia. There are three established brands and two serotypes of BoNT commercially available in most of the world, and several additional brands are available in selected geographic regions. In most controlled studies, there is significant improvement following treatment for head posture, pain and disability. The common side effects of treatment include dysphagia, dry mouth, and neck weakness. Each brand and serotype is pharmacologically distinct. The dosing of each type differs, and no simple dose equivalency has been established. With repeated treatment, the development of immunoresistance is observed in a percentage of patients. However, it is likely that each brand and serotype may differ in immunogenic potential and occurrence of secondary unresponsiveness, an issue that is currently under active investigation.
Similar content being viewed by others
References
R Benecke WH Jost P Kanovsky E Ruzicka G Comes S Grafe (2005) ArticleTitleA new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia Neurology 64 1949–1951 Occurrence Handle15955951 Occurrence Handle10.1212/01.WNL.0000163767.99354.C3 Occurrence Handle1:CAS:528:DC%2BD2MXksVaisLc%3D
B Berman L Seeberger R Kumar (2004) ArticleTitleLong-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia Mov Disord 20 233–237 Occurrence Handle10.1002/mds.20290
JW Brans R Lindeboom JW Snoek MJ Zwarts TW van Weerden ER Brunt JJ van Hilten W van der Kamp MH Prins JD Speelman (1996) ArticleTitleBotulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial Neurology 46 1066–1072 Occurrence Handle8780093 Occurrence Handle1:STN:280:DyaK28zntlyjsA%3D%3D
A Brashear MF Lew DD Dykstra CL Comella SA Factor RL Rodnitzky R Trosch C Singer MF Brin JJ Murray JD Wallace A Willmer-Hulme M Koller (1999) ArticleTitleSafety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia Neurology 53 1439–1446 Occurrence Handle10534248 Occurrence Handle1:CAS:528:DyaK1MXntlWhu7g%3D
A Brashear K Bergan J Wojcieszek ER Siemers W Ambrosius (2000) ArticleTitlePatient’s perception of stopping or continuing treatment of cervical dystonia with botulinum toxin type A Mov Disord 15 150–153 Occurrence Handle10634256 Occurrence Handle10.1002/1531-8257(200001)15:1<150::AID-MDS1024>3.0.CO;2-X Occurrence Handle1:STN:280:DC%2BD3c%2FpslOhsA%3D%3D
MF Brin MF Lew CH Adler CL Comella SA Factor J Jankovic C O’Brien JJ Murray JD Wallace A Willmer-Hulme M Koller (1999) ArticleTitleSafety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia Neurology 53 1431–1438 Occurrence Handle10534247 Occurrence Handle1:CAS:528:DyaK1MXntlWhu7s%3D
L Camfield Y Ben-Shlomo TT Warner (2002) ArticleTitleImpact of cervical dystonia on quality of life Mov Disord 17 838–841 Occurrence Handle12210891 Occurrence Handle10.1002/mds.10127
J Chan MF Brin S Fahn (1991) ArticleTitleIdiopathic cervical dystonia: clinical characteristics Mov Disord 6 119–126 Occurrence Handle2057004 Occurrence Handle10.1002/mds.870060206 Occurrence Handle1:STN:280:DyaK3M3nvVyqsw%3D%3D
CL Comella J Jankovic KM Shannon J Tsui M Swenson S Leurgans W Fan (2005) ArticleTitleComparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia Neurology 65 1423–1429 Occurrence Handle16275831 Occurrence Handle10.1212/01.wnl.0000183055.81056.5c Occurrence Handle1:STN:280:DC%2BD2Mrps12ltg%3D%3D
SR Filipovic M Jahanshahi R Viswanathan P Heywood D Rogers KP Bhatia (2004) ArticleTitleClinical features of the geste antagoniste in cervical dystonia Adv Neurol 94 191–201 Occurrence Handle14509673
DJ Gelb DH Lowenstein MJ Aminoff (1989) ArticleTitleControlled trial of botulinum toxin injections in the treatment of spasmodic torticollis Neurology 39 80–84 Occurrence Handle2642616 Occurrence Handle1:STN:280:DyaL1M%2Fot1ymuw%3D%3D
N Giladi J Meer H Kidan S Honigman (2000) ArticleTitleLong-term remission of idiopathic cervical dystonia after treatment with botulinum toxin Eur Neurol 44 144–146 Occurrence Handle11053961 Occurrence Handle10.1159/000008223 Occurrence Handle1:CAS:528:DC%2BD3cXotVCquro%3D
P Greene U Kang S Fahn M Brin C Moskowitz E Flaster (1990) ArticleTitleDouble-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis Neurology 40 1213–1218 Occurrence Handle2199847 Occurrence Handle1:STN:280:DyaK3czktVCrug%3D%3D
JM Hagenah A Vieregge P Vieregge (2001) ArticleTitleRadiculopathy and myelopathy in patients with primary cervical dystonia Eur Neurol 45 236–240 Occurrence Handle11385261 Occurrence Handle10.1159/000052135 Occurrence Handle1:STN:280:DC%2BD3MzhtFyjtg%3D%3D
J Jankovic S Leder D Warner K Schwartz (1991) ArticleTitleCervical dystonia: clinical findings and associated movement disorders Neurology 41 1088–1091 Occurrence Handle2067638 Occurrence Handle1:STN:280:DyaK3M3ps1WhsA%3D%3D
J Jankovic KD Vuong J Ahsan (2003) ArticleTitleComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia Neurology 60 1186–1188 Occurrence Handle12682332 Occurrence Handle1:STN:280:DC%2BD3s7msFSgtw%3D%3D
KR Kessler M Skutta R Benecke (1999) ArticleTitleLong-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. German Dystonia Study Group J Neurol 246 265–274 Occurrence Handle10367694 Occurrence Handle10.1007/s004150050345 Occurrence Handle1:STN:280:DyaK1M3psVWitg%3D%3D
MF Lew BT Adornato DD Duane DD Dykstra SA Factor JM Massey MF Brin J Jankovic RL Rodnitzky C Singer MR Swenson D Tarsy JJ Murray M Koller JD Wallace (1997) ArticleTitleBotulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia Neurology 49 701–707 Occurrence Handle9305326 Occurrence Handle1:CAS:528:DyaK2sXmtlOmsbk%3D
IT Lorentz SS Subramaniam C Yiannikas (1991) ArticleTitleTreatment of idiopathic spasmodic torticollis with botulinum toxin A: a double-blind study on twenty-three patients Mov Disord 6 145–150 Occurrence Handle2057005 Occurrence Handle10.1002/mds.870060210 Occurrence Handle1:STN:280:DyaK3M3nvVyqtw%3D%3D
A Marchetti R Magar L Findley JP Larsen Z Pirtosek E Ruzicka R Jech J Slawek F Ahmed (2005) ArticleTitleRetrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study Mov Disord 20 937–944 Occurrence Handle15810022 Occurrence Handle10.1002/mds.20468
T Odergren H Hjaltason S Kaakkola G Solders J Hanko C Fehling RJ Marttila H Lundh S Gedin I Westergren A Richardson C Dott H Cohen (1998) ArticleTitleA double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia J Neurol Neurosurg Psychiatry 64 6–12 Occurrence Handle9436720 Occurrence Handle1:STN:280:DyaK1c%2Fpslahsg%3D%3D
W Poewe L Schelosky B Kleedorfer F Heinen M Wagner G Deuschl (1992) ArticleTitleTreatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients J Neurol 239 21–25 Occurrence Handle1541964 Occurrence Handle10.1007/BF00839206 Occurrence Handle1:STN:280:DyaK387ns12lsA%3D%3D
W Poewe G Deuschl A Nebe E Feifel J Wissel R Benecke KR Kessler AO Ceballos-Baumann A Ohly W Oertel G Kunig (1998) ArticleTitleWhat is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group J Neurol Neurosurg Psychiatry 64 13–17 Occurrence Handle9436721 Occurrence Handle1:STN:280:DyaK1c%2Fpslahsw%3D%3D Occurrence Handle10.1136/jnnp.64.1.13
D Ranoux C Gury J Fondarai JL Mas M Zuber (2002) ArticleTitleRespective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia J Neurol Neurosurg Psychiatry 72 459–462 Occurrence Handle11909903 Occurrence Handle1:STN:280:DC%2BD387nslejsQ%3D%3D
C Sampaio J Costa JJ Ferreira (2004) ArticleTitleClinical comparability of marketed formulations of botulinum toxin Mov Disord 19 IssueIDSuppl 8 S129–S136 Occurrence Handle15027065 Occurrence Handle10.1002/mds.20066
CM Shaari I Sanders (1993) ArticleTitleQuantifying how location and dose of botulinum toxin injections affect muscle paralysis Muscle Nerve 16 964–969 Occurrence Handle8355728 Occurrence Handle10.1002/mus.880160913 Occurrence Handle1:STN:280:DyaK3szmtFSmsg%3D%3D
CM Shaari BL Wu HF Biller SK Chuang I Sanders (1998) ArticleTitleBotulinum toxin decreases salivation from canine submandibular glands Otolaryngol Head Neck Surg 118 452–457 Occurrence Handle9560094 Occurrence Handle10.1016/S0194-5998(98)70200-1 Occurrence Handle1:STN:280:DyaK1c3hvFShsw%3D%3D
D Truong DD Duane J Jankovic C Singer LC Seeberger CL Comella MF Lew RL Rodnitzky FO Danisi JP Sutton PD Charles RA Hauser GL Sheean (2005) ArticleTitleEfficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study Mov Disord 20 783–791 Occurrence Handle15736159 Occurrence Handle10.1002/mds.20403
JK Tsui A Eisen E Mak J Carruthers A Scott DB Calne (1985) ArticleTitleA pilot study on the use of botulinum toxin in spasmodic torticollis Can J Neurol Sci 12 314–316 Occurrence Handle4084867 Occurrence Handle1:STN:280:DyaL287gsFCksQ%3D%3D
JK Tsui A Eisen AJ Stoessl S Calne DB Calne (1986) ArticleTitleDouble-blind study of botulinum toxin in spasmodic torticollis Lancet 2 245–247 Occurrence Handle2874278 Occurrence Handle10.1016/S0140-6736(86)92070-2 Occurrence Handle1:STN:280:DyaL283otlOntQ%3D%3D
Author information
Authors and Affiliations
Corresponding author
Additional information
Correspondence: Cynthia L. Comella, Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA
Rights and permissions
About this article
Cite this article
Comella, C. The treatment of cervical dystonia with botulinum toxins. J Neural Transm 115, 579–583 (2008). https://doi.org/10.1007/s00702-007-0831-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-007-0831-4